Edition:
United Kingdom

Glenmark Pharmaceuticals Ltd (GLEN.NS)

GLEN.NS on National Stock Exchange of India

599.00INR
19 Oct 2018
Change (% chg)

Rs-0.70 (-0.12%)
Prev Close
Rs599.70
Open
Rs594.90
Day's High
Rs603.30
Day's Low
Rs591.00
Volume
713,818
Avg. Vol
1,045,181
52-wk High
Rs711.90
52-wk Low
Rs493.50

Summary

Name Age Since Current Position

Glenn Saldanha

47 2011 Executive Chairman of the Board, Chief Executive Officer, Managing Director

V. Mani

2018 Global Chief Financial Officer, Executive Director

Harish Kuber

2017 Compliance Officer, Company Secretary

Cherylann Pinto

2017 Director - Corporate Affairs

Rajesh Desai

52 2017 Non-Executive Director

Blanche Saldanha

2005 Non-Executive Director

Sridhar Gorthi

45 2005 Non-Executive Independent Director

Devendra Mehta

80 2009 Non-Executive Independent Director

Bernard Munos

2012 Non-Executive Independent Director

Julio Ribeiro

2003 Non-Executive Independent Director

Milind Sarwate

57 2015 Non-Executive Independent Director

Brian Tempest

65 2012 Non-Executive Independent Director

Biographies

Name Description

Glenn Saldanha

Mr. Glenn Mario Saldanha serves as Executive Chairman of the Board, Chief Executive Officer, Managing Director of Glenmark Pharmaceuticals Ltd. Mr. Saldanha joined Glenmark in 1998 as a Director, and took over as Managing Director and CEO in 2001. He has transformed the Company into a truly global organisation with revenue over a billion dollar and commercial presence in over 80 countries. Under his leadership, Glenmark has evolved from an Indian branded generics business, into a research-driven and innovation-led organisation. Mr. Saldanha’s vision is to discover, develop and take to market India’s first innovative drug for the entire world.

V. Mani

Mr. V. S. Mani has been appointed as Global Chief Financial Officer, Executive Director of the Company. He was President of the Company. He has over 25 years of experience in the corporate world.

Harish Kuber

Cherylann Pinto

Mrs. Cherylann (Cheryl) Pinto is Director - Corporate Affairs of the Company effective May 16th, 2017. Mrs. Pinto is the Director of Corporate Affairs at Glenmark since October 1999 and is an executive member of the Board. With over 28 years of experience in the pharmaceutical field, she currently heads the Company’s Corporate Communications, Corporate Affairs, IT, Admin, HR and CSR functions. She had set up a pharmaceutical company where she served as Managing Director from 1989 to 1999 before joining Glenmark.

Rajesh Desai

Mr. Rajesh V. Desai serves as Non-Executive Director of the Company. Mr. Desai is a Non-Executive Director at Glenmark Pharmaceuticals Ltd. He has over 34 years of work experience and was the Executive Director and Chief Financial Officer of Glenmark till 2016. He led the Finance, Legal and IT functions and with his strong Finance background; he contributed significantly to the growth story of Glenmark.

Blanche Saldanha

Mrs. Blanche E. Saldanha serves as Non-Executive Director of Glenmark Pharmaceuticals Ltd. Mrs. Saldanha is a Non-Executive Director and a member of the promoter group of Glenmark. Prior to this, she was the Director for exports and managed Glenmark’s international operations from 1982 to 2005. During her 23-year tenure with the organisation, she was responsible for developing and growing the Company’s export business. Dr. Tempest has been working with the pharmaceutical industry for the last four decades and has managed healthcare businesses in North America, South America, Europe, Africa, the Middle East, Australasia, China, Japan and India. He is the editor of the Journal of Generic Medicines. He is also a Non-Executive Director on the Governance Board of the United Nations Patent Pool. Dr. Brian W. Tempest Non-Executive Director - Independent Glenmark Pharmaceuticals Limited 10 Annual

Sridhar Gorthi

Mr. Sridhar Gorthi serves as Non-Executive Independent Director of Glenmark Pharmaceuticals Ltd. Mr. Gorthi is a Partner in the Mumbai office of Trilegal and his areas of expertise include M&A, joint ventures, private equity and venture capital. He has been actively involved in several high-profile cross-border transactions. Apart from representing several international clients on M&A in India, he has also advised Indian companies about outbound M&A transactions in jurisdictions, such as the UK, USA, South Africa, Argentina, Indonesia and Sri Lanka.

Devendra Mehta

Shri. Devendra Raj Mehta serves as Non-Executive Independent Director of Glenmark Pharmaceuticals Ltd. Mr. Mehta was a civil servant for almost 4 decades and has experience in administration and management of public affairs. He joined the IAS in 1961 and has held positions in the Government of Rajasthan and in the Government of India. He has served as chairman of SEBI, the deputy governor of RBI, the Director General of Foreign Trade, Ministry of Commerce and GOI.

Bernard Munos

Mr. Bernard Munos serves as Non-Executive Independent Director of Glenmark Pharmaceuticals Ltd. Mr. Munos advises organisations on being better innovators. He serves on the advisory council of the National Centre for Advancing Translational Sciences (NCATS); is a member of the National Academy of Medicine’s Forum on Drug R&D and Translation; an advisor to the journal Science Translational Medicine. His research on pharmaceutical innovation has been published in Nature and Science, as well as profiled by Forbes magazine.

Julio Ribeiro

Mr. Julio F. Ribeiro serves as Non-Executive Independent Director of Glenmark Pharmaceuticals Ltd. Mr. Ribeiro is a retired Indian police officer and civil servant, and has held increasingly responsible positions during his career. Some of the noteworthy positions include - the Commissioner of Police, Mumbai; Special Secretary to Government of India, Ministry of Home Affairs; Director General of Police, Punjab; Adviser to the Governor of Punjab; and Ambassador of India to Romania. He currently serves as Director of VVF Ltd.

Milind Sarwate

Shri. Milind Shripad Sarwate serves as Non-Executive Independent Director of the Company. Mr. Sarwate is the Founder and CEO of Increate Value Advisors LLP, a firm that facilitates organisations and individuals to discover, develop, and deliver business and social value. He has over 32 years of experience in Finance, HR and Strategy in groups like Marico and Godrej.

Brian Tempest

Dr. Brian William Tempest serves as Non-Executive Independent Director of Glenmark Pharmaceuticals Ltd. Dr. Tempest has been working with the pharmaceutical industry for the last four decades and has managed healthcare businesses in North America, South America, Europe, Africa, the Middle East, Australasia, China, Japan and India. He is the editor of the Journal of Generic Medicines. He is also a Non-Executive Director on the Governance Board of the United Nations Patent Pool.

Basic Compensation